Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 04, 2008. The report details a specific corporate action regarding the company's share capital executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 2,000,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,172.8274 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 8.99% of total voting rights).
- Shares in Issue: 5,275,770,891 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share count through a buyback program. Following the purchase on July 04, 2008, the acquired shares were cancelled. Consequently, the total number of shares in issue was updated to 5,275,770,891, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the updated share count of 5,275,770,891 for compliance with disclosure thresholds.
- Confirm the total Treasury share holding of 474,194,158 shares (8.99% of voting rights).
- Review the specific purchase price of 1,172.8274 pence per share for the 2,000,000 shares acquired.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.